Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy

Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system. A humanised anti-C5 monoclonal antibody (eculizumab) is available for the treatment of aHUS. We present the first description of atypical HUS in a child with a coexistent diagnosis of a POL-III leukodystro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Case Rep Nephrol
Päätekijät: Teoh, Chia Wei, Gorman, Kathleen Mary, Lynch, Bryan, Goodship, Timothy H. J., Dolan, Niamh Marie, Waldron, Mary, Riordan, Michael, Awan, Atif
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi 2018
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5818949/
https://ncbi.nlm.nih.gov/pubmed/29552364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2781789
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia